Two companies will jointly develop a drug for type 1 myotonic dystrophy; UK survey responders say modafinil's benefits for MMD1-related sleepiness outweigh side effects

posted on July 11, 2012 - 6:00am
Type 1 myotonic dystrophy (MMD1, or DM1) and type 2 myotonic dystrophy (MMD2, or DM2) are complex, multisystem disorders caused by similar genetic flaws on chromosome 19 (MMD1) and chromosome 3 (MMD2). Treatments that target the underlying molecular causes of MMD1 and MMD2 are in development.

Modafinil (aka Provigil) may reduce common fatigue and daytime sleepiness in ALS

posted on March 15, 2009 - 9:00pm
Study results reported in the March 2009 issue of Muscle & Nerve indicate that modafinil (marketed under the brand name Provigil) "may be a promising intervention for fatigue in ALS (amyotrophic lateral sclerosis) patients." Fatigue and daytime sleepiness often accompany this disease. Hiroshi Mitsumoto, director of the Eleanor and Lou Gehrig MDA/ALS Research Center at Columbia University...
posted on July 1, 2008 - 3:01pm
QUEST Vol. 15, No. 4
Letters to the editor discuss overcoming obstacles, facing everyday difficulties, and sleepiness and the drug Provigil.
posted on June 1, 2001 - 2:36pm
In this issue: research news on Pompe disease, Becker and Duchenne MDs, Charcot-Marie-Tooth disease, limb-girdle and myotonic MDs, spinal bulbar muscular atrophy, myasthenia gravis and nemaline myopathy